<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: KRAS status is a useful predictive marker for anti-epidermal growth factor receptor antibody therapy </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: This study aimed to examine the concordance rate of KRAS mutation status between corresponding primary and <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> lesions, and also among multiple <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, we examined the <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of KRAS mutations with respect to discordant KRAS status between primary and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumors</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN AND SETTINGS: This study was retrospective in design </plain></SENT>
<SENT sid="4" pm="."><plain>PATIENTS: Forty-three patients with <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and 113 metastatic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were studied </plain></SENT>
<SENT sid="5" pm="."><plain>MAIN OUTCOME MEASURES: The KRAS mutational status was determined by the <z:chebi fb="0" ids="48021">peptide nucleic acid</z:chebi> clamp real-time polymerase chain reaction TaqMan assay </plain></SENT>
<SENT sid="6" pm="."><plain>We also performed sequencing analysis to validate the KRAS mutational status </plain></SENT>
<SENT sid="7" pm="."><plain>When KRAS status differed between primary and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumors</z:e>, we examined the <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of KRAS status within individual <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> by microdissecting multiple samples in each patient </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: The frequency of KRAS mutations in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> was 34.9% </plain></SENT>
<SENT sid="9" pm="."><plain>A high concordance rate of KRAS (88.4-91.7%) mutations was observed between primary and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumors</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 5 cases (11.6%) with discordant KRAS status had <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> KRAS status in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>However, in 10 concordant cases <z:hpo ids='HP_0000001'>all</z:hpo> microdissected areas showed an identical KRAS mutational status within each patient </plain></SENT>
<SENT sid="12" pm="."><plain>The KRAS mutational statuses in <z:hpo ids='HP_0000001'>all</z:hpo> multiple liver and/or lung <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumors</z:e> were the same as those of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>LIMITATIONS: We could not validate KRAS status in microdissected samples by the direct sequence method that was used in the present study, because the quantity of DNA was not sufficient to perform direct sequencing </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: KRAS status in a primary site may be used for selecting patients who would benefit from anti-epidermal growth factor receptor therapy </plain></SENT>
<SENT sid="15" pm="."><plain>However, KRAS status can be <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> within a <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e>, and thus different parts of such <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> should be examined for KRAS status to correctly predict the KRAS status in metastatic lesions </plain></SENT>
</text></document>